Can technology be good for health? Investigating health-promoting strategies in the private sector.

business strategy commercial determinants of health consumer technology health impact private sector

Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2024
Historique:
received: 13 03 2024
accepted: 12 09 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

This research investigates what might motivate tech companies and impact-driven investors to adopt a health-promoting strategy in their product development and capital allocation strategies. Participants were recruited for semi-structured interviews through purposive and snowball sampling. From 83 outreach attempts, thematic saturation required 19 completed interviews out of the 46 consumer technology executives and impact-focused investors who responded. Interviews were analyzed using grounded theory-based content analysis. Seven coding categories resulted from inductive coding, with 83 sub-codes. The primary themes were: product-based health impact is magnified when matched to user demographics (making an equity mindset important); stakeholders are eager for reliable health metrics, especially those that hold across industry verticals; when capturing health impact, it is critical to include positive (i.e., economically beneficial) externalities. These results allowed for the creation of a logic model with a recommended theory of change for the private sector to develop health strategy. Intentional integration of impact strategy with business priorities will allow teams to design products that promote health, driving buy-in and resource allocation while attracting investment and double returns. For policymakers, it is clear that tech policy and regulation for corporate reporting need to keep pace. These findings are limited by the purposive recruitment of participants, introducing potential bias and risk to generalizability.

Identifiants

pubmed: 39386955
doi: 10.3389/fpubh.2024.1395422
pmc: PMC11461296
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1395422

Informations de copyright

Copyright © 2024 Sigler, Pollack Porter, Thompson, Singer and Gaskin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Brittany E Sigler (BE)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.

Keshia M Pollack Porter (KM)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.

Lindsay Thompson (L)

Carey Business School, Johns Hopkins University, Baltimore, MD, United States.

Sara Singer (S)

School of Medicine, Stanford University, Stanford, CA, United States.
Graduate School of Business, Stanford University, Stanford, CA, United States.

Darrell J Gaskin (DJ)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH